JYNNEOS® is now available as the only FDA-approved mpox vaccine in the U.S

GlobeNewswire April 2, 2024, 07:00 AM UTC

Summary: Bavarian Nordic A/S announced the commercial availability of JYNNEOS®, the only FDA-approved mpox vaccine in the U.S. Since 2022, over 32,000 mpox cases have been reported in the U.S. with 60% of eligible individuals unvaccinated. JYNNEOS is now recommended for routine use in at-risk individuals 18 years and older. The vaccine is available nationwide through healthcare providers, aiming to increase awareness and availability.

Full article

Article metrics
Significance6.1
Scale7.0
Magnitude7.5
Potential8.5
Novelty6.0
Actionability9.0
Immediacy9.5
Positivity8.0
Credibility8.0

Also covered in:

[6.0]
Bavarian Nordic launches Jynneos monkeypox vaccine in US (Pharmaceutical Technology)
[5.8]
US mpox cases double from last year, vaccination crucial (CNN)
[5.4]
Mpox cases rise in 2024, JYNNEOS vaccine recommended (Livescience.com)
[4.9]
Jynneos vaccine crucial for preventing monkeypox spread (Pharmaceutical Technology)
[4.7]
Monkeypox cases rising in the US, emphasize vaccination coverage (TheHealthSite)
[4.7]
Ontario sees spike in mpox cases, urges vaccination (CP24)